News
KYMR
40.20
+0.07%
0.03
Weekly Report: what happened at KYMR last week (0318-0322)?
Weekly Report · 3d ago
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Digital World Acquisition (DWAC) ahead of the potential listing of Trump Media & Technology. The Nevada Gaming Control Board report for February will be released. United Parcel Service (UPS) will hold its Analyst Day.
Seeking Alpha · 6d ago
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Kymera Therapeutics' shares have dropped from $81 to $39 since I wrote a note on the company in 2021. The company's technology targets the ubiquitin proteasome system to degrade disease-causing proteins. Kymera's lead candidate, KT-474, is being developed to treat autoimmune conditions. Partner Sanofi has paid $55m to take the company into Phase 2 studies. Shares have risen >130% in the past 6m.
Seeking Alpha · 03/21 20:28
Weekly Report: what happened at KYMR last week (0311-0315)?
Weekly Report · 03/18 11:06
Weekly Report: what happened at KYMR last week (0304-0308)?
Weekly Report · 03/11 11:03
Promising Future for Kymera Therapeutics: Analyst Endorses ‘Buy’ on Innovative Protein Degradation Compounds
TD Cowen analyst Marc Frahm has maintained a Buy rating on Kymera Therapeutics stock. The firm's lead compounds, KT-621 and KT-294, are poised to offer oral alternatives to injectable drugs. The company is a biotechnology company pioneering a new approach to protein degradation.
TipRanks · 03/11 03:05
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Kymera Therapeutics, Inc.: Report of proposed sale of securities
Press release · 03/05 00:31
Kymera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
Press release · 03/05 00:31
Weekly Report: what happened at KYMR last week (0226-0301)?
Weekly Report · 03/04 11:06
Kymera Therapeutics Price Target Raised to $54.00/Share From $41.00 by Truist Securities
Dow Jones · 03/01 13:44
Kymera Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 03/01 13:44
Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $54
Benzinga · 03/01 13:33
Kymera Therapeutics (KYMR) Receives a Buy from Truist Financial
TipRanks · 03/01 12:35
U.S. RESEARCH ROUNDUP-Broadcom, New York Community Bancorp, TopBuild
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Broadcom, New York Community Bancorp, and TopBuild are among the companies. Analysts raise target prices on several companies, including Bath & Body Works and Bath and Body Works.
Reuters · 03/01 06:50
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
Piper Sandler has maintained its Overweight rating of Kymera Therapeutics and raised its price target from $39.00 to $56.00. The company is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. Shares of kymera therapeutics are trading down 0.07% over the last 24 hours.
Benzinga · 02/27 17:00
Kymera Therapeutics Price Target Raised to $56.00/Share From $39.00 by Piper Sandler
Dow Jones · 02/27 15:38
Kymera Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 02/27 15:38
Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $56
Benzinga · 02/27 15:27
Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
TipRanks · 02/27 12:43
More
Webull provides a variety of real-time KYMR stock news. You can receive the latest news about Kymera Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KYMR
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.